- Home
- NUVB vs RZAI Comparison
NUVB vs RZAI Comparison
Compare NUVB & RZAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUVB | RZAI |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | NUVB | RZAI |
|---|---|---|
| Price | $4.50 | $10.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 5.0M | 147.4K |
| Earning Date | 11-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,902,000.00 | N/A |
| Revenue This Year | $209.36 | N/A |
| Revenue Next Year | $41.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 698.96 | N/A |
| 52 Week Low | $3.92 | $9.03 |
| 52 Week High | $9.75 | $20.45 |
Technical Indicators
Market Signals| Indicator | NUVB | RZAI |
|---|---|---|
| Relative Strength Index (RSI) | 31.70 | 20.82 |
| Support Level | $4.45 | $9.03 |
| Resistance Level | $5.16 | $11.87 |
| Average True Range (ATR) | 0.24 | 1.43 |
| MACD | 0.02 | 0.18 |
| Stochastic Oscillator | 16.78 | 16.85 |
Price Performance
Historical ComparisonAbout NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.